Hostname: page-component-cd9895bd7-gbm5v Total loading time: 0 Render date: 2024-12-22T22:08:05.509Z Has data issue: false hasContentIssue false
  • English
  • Français

Risk Factors for gyrA and parC Mutations in Pseudomonas aeruginosa

Published online by Cambridge University Press:  23 January 2015

Valerie C. Cluzet ,
Ebbing Lautenbach ,
Irving Nachamkin ,
Mark S. Cary ,
Neil O. Fishman ,
Natalie N. C. Shih ,
Knashawn H. Morales  and
Darren R. Linkin
Valerie C. Cluzet*
Affiliation:
Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
Ebbing Lautenbach
Affiliation:
Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
Irving Nachamkin
Affiliation:
Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
Mark S. Cary
Affiliation:
Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
Neil O. Fishman
Affiliation:
Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
Natalie N. C. Shih
Affiliation:
Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
Knashawn H. Morales
Affiliation:
Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
Darren R. Linkin
Affiliation:
Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
*
Address correspondence to Valerie Cluzet, MD, Division of Infectious Diseases, Department of Medicine, Hospital of the University of Pennsylvania, 3400 Spruce Street, 3rd Floor, Silverstein Building, Ste. E, Philadelphia, PA 19104 ([email protected]).
Get access Rights & Permissions [Opens in a new window]

Abstract

OBJECTIVE

The major mechanism of fluoroquinolone (FQ) resistance in Pseudomonas aeruginosa (PSA) is modification of target proteins in DNA gyrase and topoisomerase IV, most commonly the gyrA and parC subunits. The objective of this study was to determine risk factors for PSA with and without gyrA or parC mutations.

DESIGN

Case-case-control study

SETTING

Two adult academic acute-care hospitals

PATIENTS

Case 1 study participants had a PSA isolate on hospital day 3 or later with any gyrA or parC mutation; case 2 study participants had a PSA isolate on hospital day 3 or later without these mutations. Controls were a random sample of all inpatients with a stay of 3 days or more.

METHODS

Each case group was compared to the control group in separate multivariate models on the basis of demographics and inpatient antibiotic exposure, and risk factors were qualitatively compared.

RESULTS

Of 298 PSA isolates, 172 (57.7%) had at least 1 mutation. Exposure to vancomycin and other agents with extended Gram-positive activity was a risk factor for both cases (case 1 odds ratio [OR], 1.09; 95% confidence interval [CI], 1.04–1.13; OR, 1.14; 95% CI, 1.03–1.26; case 2 OR, 1.09; 95% CI, 1.03–1.14; OR, 1.13; 95% CI, 1.01–1.25, respectively).

CONCLUSIONS

Exposure to agents with extended Gram-positive activity is a risk factor for isolation of PSA overall but not for gyrA/parC mutations. FQ exposure is not associated with isolation of PSA with mutations.

Infect Control Hosp Epidemiol 2015;00(0): 1–7

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 36 , Issue 4 , April 2015 , pp. 387 - 393
Copyright
© 2015 by The Society for Healthcare Epidemiology of America. All rights reserved 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

PREVIOUS PRESENTATION. These results were presented in abstract form at the Interscience Conference on Antimicrobial Agents and Chemotherapy in Denver, Colorado, September 10–13, 2013.

References

REFERENCES

1. Gaynes, R, Edwards, JR. National Nosocomial Infections Surveillance S. Overview of nosocomial infections caused by Gram-negative bacilli. Clin Infect Dis 2005;41:848–854.Google Scholar
2. Livermore, DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002;34:634–640.Google Scholar
3. Aloush, V, Navon-Venezia, S, Seigman-Igra, Y, Cabili, S, Carmeli, Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 2006;50:43–48.Google Scholar
4. Cao, B, Wang, H, Sun, H, Zhu, Y, Chen, M. Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections. J Hosp Infect 2004;57:112–118.Google Scholar
5. Carmeli, Y, Troillet, N, Karchmer, AW, Samore, MH. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa . Arch Intern Med 1999;159:1127–1132.Google Scholar
6. National Nosocomial Infections Surveillance S. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470–485.Google Scholar
7. Jalal, S, Wretlind, B. Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa . Microbial Drug Resist 1998;4:257–261.Google Scholar
8. Lee, JK, Lee, YS, Park, YK, Kim, BS. Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa . Int J Antimicrob Agent 2005;25:290–295.Google Scholar
9. Qiang, YZ, Qin, T, Fu, W, Cheng, WP, Li, YS, Yi, G. Use of a rapid mismatch PCR method to detect gyrA and parC mutations in ciprofloxacin-resistant clinical isolates of Escherichia coli . J Antimicrob Chemother 2002;49:549–552.Google Scholar
10. Bagel, S, Hullen, V, Wiedemann, B, Heisig, P. Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli . Antimicrob Agents Chemother 1999;43:868–875.CrossRefGoogle ScholarPubMed
11. Gasink, LB, Fishman, NO, Weiner, MG, Nachamkin, I, Bilker, WB, Lautenbach, E. Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact. Am J Med 2006;119(526):e519–e525.Google Scholar
12. Hsu, DI, Okamoto, MP, Murthy, R, Wong-Beringer, A. Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomes. J Antimicrob Chemother 2005;55:535–541.Google Scholar
13. Baddour, LM, Hicks, DV, Tayidi, MM, et al. Risk factor assessment for the acquisition of fluoroquinolone-resistant isolates of Pseudomonas aeruginosa in a community-based hospital. Microbial Drug Resist 1995;1:219–222.Google Scholar
14. Paladino, JA, Sunderlin, JL, Forrest, A, Schentag, JJ. Characterization of the onset and consequences of pneumonia due to fluoroquinolone-susceptible or -resistant Pseudomonas aeruginosa . J Antimicrob Chemother 2003;52:457–463.Google Scholar
15. Khayr, W, Rheault, W, Waiters, L, Walters, A. Epidemiology of ciprofloxacin-resistant Pseudomonas aeruginosa in a veterans affairs hospital. Am J Therapeut 2000;7:309–312.CrossRefGoogle Scholar
16. Kaye, KS, Harris, AD, Samore, M, Carmeli, Y. The case-case-control study design: addressing the limitations of risk factor studies for antimicrobial resistance. Infect Control Hosp Epidemiol 2005;26:346–351.Google Scholar
17. Lautenbach, E, Weiner, MG, Nachamkin, I, Bilker, WB, Sheridan, A, Fishman, NO. Imipenem resistance among pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infect Control Hosp Epidemiol 2006;27:893–900.Google Scholar
18. Elixhauser, A, Steiner, C, Harris, DR, Coffey, RM. Comorbidity measures for use with administrative data. Med Care 1998;36:8–27.Google Scholar
19. Baram, D, Daroowalla, F, Garcia, R, et al. Use of the All Patient Refined-Diagnosis Related Group (APR-DRG) risk of mortality score as a severity adjustor in the medical ICU. Clin Med Circ Resp Pulm 2008;2:19–25.Google Scholar
20. Micek, ST, Lloyd, AE, Ritchie, DJ, Reichley, RM, Fraser, VJ, Kollef, MH. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005;49:1306–1311.Google Scholar
21. Averill, RF, Goldfield, N, Steinbeck, B, Grant, T, Muldoon, J, Brough, J, Gay, J. Development of the all patient refined DRGs (APR-DRGs). 3M HIS Research Report, 1997.Google Scholar
22. Institute of Clinical and Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing. CLSI. Wayne, PA: Clinical and Laboratory Standards Institute; 2010.Google Scholar
23. Gorgani, N, Ahlbrand, S, Patterson, A, Pourmand, N. Detection of point mutations associated with antibiotic resistance in Pseudomonas aeruginosa. Int J Antimicrob Agents 2009;34:414–418.CrossRefGoogle Scholar
24. Sanger Sequencing on ABI 3730. Perelman School of Medicine Department of Genetics DNA Sequencing Facility website. Available from: http://www.med.upenn.edu/genetics/dnaseq/sanger.shtml. Accessed July 22, 2014.Google Scholar
25. Sun, GW, Shook, TL, Kay, GL. Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis. J Clin Epidemiol 1996;49:907–916.Google Scholar
26. Mickey, RM, Greenland, S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol 1989;129:125–137.Google Scholar
27. Harris, AD, Perencevich, E, Roghmann, MC, Morris, G, Kaye, KS, Johnson, JA. Risk factors for piperacillin-tazobactam-resistant Pseudomonas aeruginosa among hospitalized patients. Antimicrob Agents Chemother 2002;46:854–858.Google Scholar
28. Harris, AD, Smith, D, Johnson, JA, Bradham, DD, Roghmann, MC. Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients. Clin Infect Dis 2002;34:340–345.Google Scholar